丘脑中央中核深部脑刺激治疗Lennox-Gastaut综合征(ESTEL试验)
ESTEL试验是一项前瞻性、双盲、随机研究,评估丘脑中央中核深部脑刺激(CM-DBS)治疗Lennox-Gastaut综合征(LGS)的疗效与安全性。19例患者随机分入刺激组(n=10)和对照组(n=9),盲期结束时刺激组50%患者日记记录的癫痫发作减少≥50%,对照组为22%(OR=3.1,95%CI=0.44-21.45,p=0.25);电graphic发作减少≥50%的比例刺激组为59%,对照组为0%(OR=23.25,95%CI=1.0-538.4,p=0.05)。结论认为CM-DBS在3个月刺激后减少了电graphic发作而非日记记录的发作,所有患者研究结束时50%的患者日记记录的发作减半。
要点
- 盲期结束时刺激组50%患者日记记录发作减少≥50%,对照组22%(OR=3.1,95%CI=0.44-21.45,p=0.25)。
- 盲期结束时刺激组59%患者电graphic发作减少≥50%,对照组0%(OR=23.25,95%CI=1.0-538.4,p=0.05)。
- 所有患者研究结束时日记记录发作中位减少46.7%(IQR=28-67%),电graphic发作中位减少53.8%(IQR=27-73%)。
核心结论
- CM-DBS在3个月刺激后减少了LGS患者的电graphic发作而非日记记录的发作。
- 所有参与者中50%在研究结束时日记记录的发作减半,提供了治疗效应的支持性证据。
研究设计与样本
- 前瞻性、双盲、随机研究,评估连续循环刺激CM-DBS治疗LGS。
- 2017年11月至2019年12月在澳大利亚单中心纳入20例LGS年轻成人(17-37岁;13例女性),均接受双侧CM-DBS,其中19例随机(治疗组n=10,对照组n=9)。
主要发现
- 盲期结束时,刺激组50%患者日记记录发作减少≥50%,对照组22%(OR=3.1,95%CI=0.44-21.45,p=0.25)。
- 盲期结束时,刺激组59%患者电graphic发作减少≥50%,对照组0%(OR=23.25,95%CI=1.0-538.4,p=0.05)。
- 所有患者中,日记记录发作中位减少46.7%(IQR=28-67%),电graphic发作中位减少53.8%(IQR=27-73%)(基线 vs 研究结束)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior uncontrolled studies have reported seizure reductions following deep brain stimulation (DBS) in patients with Lennox-Gastaut syndrome (LGS), but evidence from randomized controlled studies is lacking. We aimed to formally assess the efficacy and safety of DBS to the centromedian thalamic nucleus (CM) for the treatment of LGS. METHODS: We conducted a prospective, double-blind, randomized study of continuous, cycling stimulation of CM-DBS, in patients with LGS. Following pre- and post-implantation periods, half received 3 months of stimulation (blinded phase), then all received 3 months of stimulation (unblinded phase). The primary outcome was the proportion of participants with ≥50% reduction in diary-recorded seizures in stimulated versus control participants, measured at the end of the blinded phase. A secondary outcome was the proportion of participants with a ≥50% reduction in electrographic seizures on 24-hour ambulatory electroencephalography (EEG) at the end of the blinded phase. RESULTS: Between November 2017 and December 2019, 20 young adults with LGS (17-37 years;13 women) underwent bilateral CM-DBS at a single center in Australia, with 19 randomized (treatment, n = 10 and control, n = 9). Fifty percent of the stimulation group achieved ≥50% seizure reduction, compared with 22% of controls (odds ratio [OR] = 3.1, 95% confidence interval [CI] = 0.44-21.45, p = 0.25). For electrographic seizures, 59% of the stimulation group had ≥50% reduction at the end of the blinded phase, compared with none of the controls (OR= 23.25, 95% CI = 1.0-538.4, p = 0.05). Across all patients, median seizure reduction (baseline vs study exit) was 46.7% (interquartile range [IQR] = 28-67%) for diary-recorded seizures and 53.8% (IQR = 27-73%) for electrographic seizures. INTERPRETATION: CM-DBS in patients with LGS reduced electrographic rather than diary-recorded seizures, after 3 months of stimulation. Fifty percent of all participants had diary-recorded seizures reduced by half at the study exit, providing supporting evidence of the treatment effect. ANN NEUROL 2022;91:253-267.
引用
- Dalic LJ, Warren AEL, Bulluss KJ, et al. DBS of Thalamic Centromedian Nucleus for Lennox-Gastaut Syndrome (ESTEL Trial). Ann Neurol. 2021. PMID: 34877694. doi:10.1002/ana.26280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。